Phathom Pharmaceuticals

World Rank (Aug-2026)

10409

Market Cap (Aug-2026)

0.775 Billion USD

Market Cap (Mar-08-2026)

0.841 Billion USD

World Rank (Jan-05-2024)

12,344

Market Cap (Jan-05-2024)

0.521 Billion USD

World Rank (Jul-30-2023)

9,683

Market Cap (Jul-30-2023)

0.835 Billion USD

World Rank (Jan-07-2022)

13,041

Market Cap (Jan-07-2022)

0.528 Billion USD

World Rank (Jan-01-2021)

8,215

Market Cap (Jan-01-2021)

0.936 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

PHAT

Employee Count

77

Employee Count as of Date

As on 2021

Headquarters City/State

New Jersey

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

175 Million USD

Annual Operating Income in USD

-160 Million USD

Annual Net Income in USD

-221 Million USD

Annual Results for Period Ending

For year ending December-2025

Total Assets in USD

259 Million USD

Total Liabilities in USD

697 Million USD

Total Equity in USD

-438 Million USD

Balance Sheet for Period Ending

As of December-2025

Business Sector

Company Website

PHATHOM PHARMACEUTICALS

Yahoo

Yahoo @ Nasdaq

Company Profile

Phathom Pharmaceuticals is a Clinical Stage Biopharmaceutical company committed to transforming the treatment landscape and improving the lives of patients suffering from acid related gastrointestinal (GI) disorders. The company annual revenue is approximately 74.5 million USD, total assets is 263.9 million USD and 16 employees as on 2019. The headquarters is in USA.

Founded Year

2018

IPO Year

2019

Stock Exchange

Nasdaq

Nasdaq Sector

Health Care

Nasdaq Industry

Biotechnology: Pharmaceutical Preparations